Dyne Therapeutics, Inc. Proceeds from Issuance of Convertible Preferred Stock
Dyne Therapeutics, Inc. (DYN) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2022-03-10
- Dyne Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-12-31 was -$134.00K.
- Dyne Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-09-30 was $132.95M.
- Dyne Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-06-30 was $0.00.
- Dyne Therapeutics, Inc. proceeds from issuance of convertible preferred stock for the quarter ending 2020-03-31 was $1.97M.
- Dyne Therapeutics, Inc. proceeds from issuance of convertible preferred stock for fiscal 2020 was $134.79M, a 574.30% increase from fiscal 2019.
- Dyne Therapeutics, Inc. proceeds from issuance of convertible preferred stock for fiscal 2019 was $19.99M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | |||
| 2020-12-31 | -$134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $132.81M derived: sum of 2 quarters · filed 2022-03-10 | $132.81M derived: sum of 3 quarters · filed 2022-03-10 | $134.79M 10-K · filed 2022-03-10 |
| 2020-09-30 | $132.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $132.95M derived: sum of 2 quarters · filed 2021-11-04 | $134.92M 10-Q · filed 2021-11-04 | $134.92M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.97M 10-Q · filed 2021-08-05 | $1.97M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.97M 10-Q · filed 2021-05-06 | $1.97M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $19.99M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $19.99M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |